Dupixent

News

GSK sets up Nucala and Dupixent showdown in COPD

GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.

Market Access

Sanofi's Dupixent gets FDA nod for chronic hives indication

Dupixent's seventh indication is chronic hives, where a new treatment hasn't been approved since Novartis's Xolair in 2014

News

Can Dupixent plug treatment gap in bullous pemphigoid?

The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.

News

Sanofi's Dupixent scores double COPD win in US, China

Originally anticipated in June, the FDA action stands to make Sanofi and Regeneron's biologic blockbuster even bigger.

News

Dupixent delivers in two skin disease trials

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications f

News

GSK says Nucala hits the target in new COPD trial

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<

GSK sets up Nucala and Dupixent showdown in COPD

Sanofi's Dupixent gets FDA nod for chronic hives indication

Can Dupixent plug treatment gap in bullous pemphigoid?

Sanofi's Dupixent scores double COPD win in US, China

Dupixent delivers in two skin disease trials

GSK says Nucala hits the target in new COPD trial

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Dupixent

Editor's Picks